Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Their Variations as a Basis for a Prediction Model in Advanced NSCLC Patients Receiving Anlotinib

Table 3

Associations of NLR, PLR, and their variations with treatment response.

Treatment response	Pre-NLR			Pre-PLR			Post-NLR variation			Post-PLR variation
	≤ 3.41	> 3.41	value	≤ 205.63	>205.63	value	Decrease	Rise	value	Decrease	Rise	value
PR	7 (4.6%)	3 (2.0%)	0.019	7 (4.6%)	3 (2.0%)	0.016	6 (3.9%)	4 (2.6%)	0.037	5 (3.3%)	5 (3.3%)	0.642
SD	56 (36.8%)	42 (27.6%)		62 (40.8%)	36 (23.7%)		58 (38.2%)	40 (26.3%)		61 (40.1%)	37 (24.3%)
PD	15 (9.9%)	29 (19.1%)		17 (11.2%)	27 (17.8%)		16 (10.5%)	28 (18.4%)		29 (19.1%)	15 (9.9%)
ORR	4.6%	2.0%	0.329	4.6%	2.0%	0.515	3.9%	2.6%	0.749	3.3%	3.3%	0.398
DCR	41.4%	29.6%	0.007	45.4%	25.7%	0.004	42.1%	28.9%	0.010	43.4%	27.6%	0.579

analyzed with chi-square test. analyzed with Fisher.